Tovecimig

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameTovecimig
Drug Alias NameNOV-1501ES-104CTX-009HD-B001AHDB001A +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionDelta-like protein 4 inhibitorsVascular endothelial growth factor A inhibitors
TargetsDelta-like protein 4Vascular endothelial growth factor A
Therapy Area/IndicationsSolid tumoursAmpullary CarcinomaRectal Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth KoreaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAbl Bio Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCompass Therapeutics LLCCông Ty Trách Nhiệm Hữu Hạn Binex Line Việt NamCompass Therapeutics Inc +[6] 
Inactive CompaniesAbl Bio IncHandok Inc
Active IndicationsSolid tumoursAmpullary CarcinomaRectal Neoplasms +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A